Yan Leyfman: A phase 1 trial of IMA203 shows promising activity in HLA-A*02+ patients with PRAME+ refractory solid tumors
Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn about a paper by Martin Wermke et al. published in Nature Medicine:
“In contrast to CAR T cells, TCR-engineered T cells can target intracellular tumor-associated antigens – critical in tackling solid tumors.
A phase 1 trial of IMA203, a PRAME-directed TCR-T therapy, shows promising activity in HLA-A*02+ patients with PRAME+ refractory solid tumors (like melanoma and sarcoma).
- 41 patients treated
- 52.5% overall response rate
- 28.9% confirmed responses
- Low rates of severe CRS (4.9%)
- Rapid engraftment, long-term persistence
- Stronger responses linked to higher PRAME expression and T cell infiltration
Bottom line: IMA203 is safe, durable, and shows encouraging anti-tumor activity across multiple solid tumor types. More to come!
ClinicalTrials.gov: NCT03686124.”
“Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial”
Authors: Martin Wermke, Dejka Araurjo, Manik Chatterjee, Apostolia Tsimberidou, Tobias Holderried, Harpreet Singh-Jasuja, Steffen Walter, Toni Weinschenk, Jason Luke, Cedrik Britten et al.
More posts featuring Yan Leyfman.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023